{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:06:13Z","timestamp":1793297173457,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cidara Therapeutics, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rezafungin (RZF) is a novel echinocandin exhibiting distinctive pharmacokinetics\/pharmacodynamics. STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin (CAS) once daily for treatment of candidemia and\/or invasive candidiasis (IC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with systemic signs and mycological confirmation of candidemia and\/or IC were randomized to RZF 400 mg QWk (400 mg), RZF 400 mg on week 1 then 200 mg QWk (400\/200 mg), or CAS 70 mg as a loading dose followed by 50 mg daily for \u22644 weeks. Efficacy assessments included overall cure (resolution of signs of candidemia\/IC + mycological eradication) at day 14 (primary endpoint), investigator-assessed clinical response at day 14, and 30-day all-cause mortality (ACM) (secondary endpoints), and time to negative blood culture. Safety was evaluated by adverse events and ACM through follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 207 patients enrolled, 183 were in the microbiological intent-to-treat population (~21% IC). Overall cure rates were 60.5% (46\/76) for RZF 400 mg, 76.1% (35\/46) for RZF 400\/200 mg, and 67.2% (41\/61) for CAS; investigator-assessed clinical cure rates were 69.7% (53\/76), 80.4% (37\/46), and 70.5% (43\/61), respectively. In total, 30-day ACM was 15.8% for RZF 400 mg, 4.4% for RZF 400\/200 mg, and 13.1% for CAS. Candidemia was cleared in 19.5 and 22.8 hours in RZF and CAS patients, respectively. No concerning safety trends were observed; ACM through follow-up was 15.2% (21\/138) for RZF and 18.8% (13\/69) for CAS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RZF was safe and efficacious in the treatment of candidemia and\/or IC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT02734862<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1380","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T15:17:04Z","timestamp":1600183024000},"page":"e3647-e3655","source":"Crossref","is-referenced-by-count":153,"title":["Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial"],"prefix":"10.1093","volume":"73","author":[{"suffix":"III","given":"George R","family":"Thompson","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Division of Infectious Diseases and Department of Medical Microbiology and Immunology, University of California Davis Medical Center, Sacramento, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic de Barcelona, IDIBAPS, University of Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Skoutelis","sequence":"additional","affiliation":[{"name":"Department of Medicine and Infectious Diseases, Evangelismos General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Infectious Disease, Medical College of Georgia\/Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Honore","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Brugmann University Hospital, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P","family":"Horcajada","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Universitat Aut\u00f2noma de Barcelona (UAB), Universitat Pompeu Fabra (UPF), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Spapen","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, University Hospital Brussels, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Department of Health Sciences University of Genoa and Policlinico San Martino IST, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ostrosky-Zeichner","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, McGovern Medical School, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita F","family":"Das","sequence":"additional","affiliation":[{"name":"AD Stat Consulting, Guerneville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando M","family":"Viani","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Sandison","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"Pappas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"2021121011253204500_CIT0001","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021121011253204500_CIT0002","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2021121011253204500_CIT0003","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021121011253204500_CIT0004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2021121011253204500_CIT0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011253204500_CIT0006","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1093\/jac\/dkv173","article-title":"Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis","volume":"70","author":"Grau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021121011253204500_CIT0007","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1128\/AAC.00621-11","article-title":"Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts","volume":"55","author":"Howard","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011253204500_CIT0008","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1093\/jac\/dkx448","article-title":"We can do better: a fresh look at echinocandin dosing","volume":"73","author":"Bader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021121011253204500_CIT0009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011253204500_CIT0010","doi-asserted-by":"crossref","first-page":"7601","DOI":"10.1128\/AAC.04134-14","article-title":"Abdominal candidiasis is a hidden reservoir of echinocandin resistance","volume":"12","author":"Shields","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011253204500_CIT0011","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011253204500_CIT0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02154-17","article-title":"Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011253204500_CIT0013","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/jac\/dky153","article-title":"Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model","volume":"8","author":"Hager","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021121011253204500_CIT0014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01556-19","article-title":"Determination of pharmacodynamic target exposures for rezafungin against Candida tropicalis and Candida dubliniensis in the neutropenic mouse disseminated candidiasis model","volume":"63","author":"Lepak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011253204500_CIT0015","doi-asserted-by":"crossref","first-page":"e00546","DOI":"10.1002\/prp2.546","article-title":"Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: insights on the PK\/PD pharmacometrics of rezafungin efficacy","volume":"6","author":"Miesel","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"2021121011253204500_CIT0016","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/cpdd.757","article-title":"Lack of effect of rezafungin on QT\/QTc interval in healthy subjects","volume":"9","author":"Flanagan","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2021121011253204500_CIT0017","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2021121011253204500_CIT0018","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1080\/13693780802428542","article-title":"Paradoxical echinocandin activity: a limited in vitro phenomenon?","volume":"47","author":"Wiederhold","year":"2009","journal-title":"Med Mycol"},{"key":"2021121011253204500_CIT0019","article-title":"9th trends in medical mycology held on 11\u201314 October 2019, Nice, France, organized under the auspices of EORTC-IDG and ECMM","volume":"5","author":"Gangneux","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"2021121011253204500_CIT0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.bmt.1705559","article-title":"High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation","volume":"3","author":"Safdar","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2021121011253204500_CIT0021","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/0897190013515927","article-title":"High-dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic stem cell transplantation: a critical review of short-term and long-term adverse events","volume":"28","author":"Safdar","year":"2015","journal-title":"J Pharm Pract"},{"key":"2021121011253204500_CIT0022","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1086\/598933","article-title":"A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis","volume":"48","author":"Betts","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2021121011253204500_CIT0023","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.3109\/10428194.2014.885514","article-title":"Safety of high-dose micafungin for patients with hematological diseases","volume":"55","author":"Yamazaki","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2021121011253204500_CIT0024","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2021121011253204500_CIT0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/jac\/dkw352","article-title":"Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation","volume":"72","author":"Jullien","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021121011253204500_CIT0026","doi-asserted-by":"crossref","first-page":"S643","DOI":"10.1093\/cid\/civ817","article-title":"Intermittent dosing of micafungin is effective for treatment of experimental disseminated candidiasis in persistently neutropenic rabbits","volume":"61","author":"Petraitiene","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021121011253204500_CIT0027","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/cmi.12640","article-title":"CD101: a novel long-acting echinocandin","volume":"18","author":"Zhao","year":"2016","journal-title":"Cell Microbiol"},{"key":"2021121011253204500_CIT0028","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13054-018-2019-8","article-title":"Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients","volume":"22","author":"Maseda","year":"2018","journal-title":"Crit Care"},{"key":"2021121011253204500_CIT0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00063-18","article-title":"Pharmacokinetics of anidulafungin in obese and normal-weight adults","volume":"62","author":"Wasmann","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1380\/38820697\/ciaa1380.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3647\/41608198\/ciaa1380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3647\/41608198\/ciaa1380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T06:46:52Z","timestamp":1696661212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/11\/e3647\/5909460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,9,21]]},"published-print":{"date-parts":[[2021,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1380","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2020,9,21]]}}}